Proposed changes to the EU in vitro diagnostic medical devices (IVDR) legislation, and the EU Biotech Act I, help address key ESMO concerns on fragmented procedures, lower-risk testing, central laboratories and multinational oncology studies, ensuring more equitable access to innovative oncology treatment for all patients with cancer
